Elevation Oncology Inc (ELEV) Stock: What Does the Chart Say Tuesday?

Elevation Oncology Inc (ELEV) stock is higher by 7.41% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Elevation Oncology Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ELEV!

See Full ELEV Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ELEV Stock Today?

Elevation Oncology Inc (ELEV) stock is trading at $1.16 as of 3:37 PM on Tuesday, Oct 4, a gain of $0.01, or 1% from the previous closing price of $1.15. The stock has traded between $1.15 and $1.22 so far today. Volume today is less active than usual. So far 45,400 shares have traded compared to average volume of 61,688 shares. To see InvestorsObserver's Sentiment Score for Elevation Oncology Inc click here.

More About Elevation Oncology Inc

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition. Click Here to get the full Stock Report for Elevation Oncology Inc stock.